Introduction
An American clinical emergency is the occurrence of acute kernicterus in the 21st century. Unmonitored common signs of newborn jaundice and hyperbilirubinemia (otherwise easily treated with phototherapy), unrecognized or untreated in a timely manner, can cause serious and often irreversible post-icteric outcomes. Neonatal hyperbilirubinemia occurs in all newborn infants and may be recognized as jaundice in about 60% of healthy newborns in the United States. Most infants are cared for at home at the age of >72 h during the usual peak hyperbilirubinemia (age: 72 to 120 h). Jaundice and hyperbilirubinemia should be benign and resolved by the age of 2 to 3. Significant hyperbilirubinemia (>95th percentile for age in hours) occurs in 8 to 11% of infants. 1, 2 The etiological basis for progressive hyperbilirubinemia is multifactorial and due to excessive bilirubin production and/or decrease its elimination is influenced by both constitutional and environmental factors. In 1994, the Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia of the American Academy of Pediatrics (AAP) published a practice parameter to manage hyperbilirubinemia in the healthy term newborns. 3 Updated 2004 clinical practice guidelines address concerns regarding the risk of kernicterus and represent a consensus of the committee charged by the AAP with a careful review of evidence and literature. 4, 5 A number of questions impact daily clinical practice. Governed by concerns for patient safety, clinical practice needs to range from reassurance, alerts and concerns of alarm for target populations in the continuum of progressive hyperbilirubinemia. Some of the questions that clinicians have been asked are addressed below in the context of available evidence.
Frequently asked questions
Question I: Does bilirubin damage the brain of healthy infants? Yes. Prior to publication of the 1994 AAP recommendations, the 'lack of evidence' of bilirubin neurotoxicity in term apparently healthy babies in the pediatric literature promoted a kinder, gentler, demedicalized management of neonatal hyperbilirubinemia. [6] [7] [8] These assertions excluded infants with Crigler-Najjar syndrome who were healthy at birth but subsequently progressed to severe hyperbilirubinemia and some sustained kernicterus. At present, documented cases of classic kernicterus in breast-fed infants discharged as healthy from their birth hospitals confirm that bilirubin can be neurotoxic in the absence of hemolytic disease.
9,10
Question 2: Is there a re-emergence of kernicterus in the United States? Possibly, yes. Soon after publications of articles 7, 8 questioning the occurrence of kernicterus in term infants without hemolytic disease (as discussed above), reports of kernicterus in term healthy newborns appeared. 9 Due to the absence of formal reporting for incidence of kernicterus or of its surrogate, extreme hyperbilirubinemia, it has been a challenge to gauge the magnitude of its reemergence. Clinical reports from the Pilot USA Kernicterus Registry presented in this supplement provide evidence for the 'tip of the iceberg' of the adverse outcomes of unrecognized and unmonitored neonatal hyperbilirubinemia. 10 Question 3: Was kernicterus previously prevented in the United States? Probably, yes. Ip et al. 5 compiled voluntary reports of kernicterus in the pediatric literature for the past 5 decades. We juxtaposed the date of births of these infants to the prevalent and changing clinical practices in bilirubin management (Table 1 ). Prior to the introduction of exchange transfusion, severe neonatal hyperbilirubinemia was generally due to Rh hemolytic disease and perinatal sepsis, and often complicated with birth asphyxia. Kernicterus was one of the major pediatric problems in the early 20th century (prior to the 1950s). Over the ensuing five decades due to prenatal diagnosis of Rh isoimmunization and use of exchange transfusions as neonatal intensive care was refined, evidence-based management of Rh disease was delineated. Concurrently, the availability of Rhogam reduced the incidence of Rh isoimmunization and hemolysis. Advent of phototherapy and its liberal use in the United States in the late 1960s and early 1970s led to the effective management of severe neonatal hyperbilirubinemia. 11 Unfortunately, evidence-based studies were not conducted to show its effectiveness in preventing kernicterus. The inherent ability of phototherapy to reduce bilirubin concentrations led to a widespread clinical practice for a staged approach of using phototherapy prior to exchange transfusion. As shown in Table 1 , the least number of cases of kernicterus were reported in the pediatric literature from 1973 to 1982. During this time period, liberal phototherapy with white light devices was readily adopted and implemented by pediatricians who relied extensively on exchange transfusion for total serum bilirubin (TSB) levels >20 mg per 100 ml. Changing demographics, healthcare practices and waning experiences of infants with severe hemolytic diseases in the newborn characterized the 1990s. A resurgence of kernicterus was reported in infants that were being cared for in a home environment, often with limited medical supervision, during the first week after birth.
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Question 4: What was the public health impact on the 1994 AAP Guidelines? Implementation and surveillance strategies were not planned. No formal public health evaluation of the impact of the 1994 practice parameters was initiated to track national incidence of kernicterus or its surrogate, extreme hyperbilirubinemia. To track the cases of kernicterus encountered by colleagues, Dr Audrey K Brown initiated an informal voluntary registry of cases at the 1992 Kernicterus symposium (Pediatric Academic Societies). Evidence from this convenient sample led to a systems approach to manage newborn jaundice. 10, 12 This inquiry of 'numerators' does not provide any incidence or prevalence of kernicterus in the US population, rather it provides insight into the occurrence for a condition where nationally recommended guidelines either were not implemented or failed to identify an infant with progressive severe hyperbilirubinemia.
Question 5: What is the current incidence of kernicterus and severe neonatal hyperbilirubinemia? Approximately 1 in 650 to 1000 infants, >35 weeks of gestation can develop serum bilirubin values of 427 mmol l À1 (>25 mg per 100 ml) and approximately 1 in 10 000 have levels of 513 mmol l À1 (>30 mg per 100 ml). 13 There is a varying occurrence of infants with total bilirubin levels >25 mg per 100 ml from diverse communities and practices (Table 2) . There are few population-based studies on the incidence of either acute bilirubin encephalopathy and/or chronic bilirubin encephalopathy (kernicterus). Incidence of chronic kernicterus in North America and Europe is listed in Table 3 . In Denmark, there were no case reports of kernicterus in the 20 years prior to Ebbesen's report 14 15 A 2004 UK surveillance study has reported an occurrence of kernicterus in 1 in 100 000 live births. 16 The frequency of catastrophic hyperbilirubinemia (serum bilirubin 513 mmol l À1 ) was 1 in 14 084 live births in the United Kingdom. 16 A 2004 Canadian survey assessed the frequency of extreme hyperbilirubinemia (serum bilirubin >427 mmol l À1 ) as 1 in 2840 live births, of which 13 (2/100 000 live births) had abnormal neurological outcomes at the time of discharge. 17 Use of phototherapy and exchange transfusion during the development and implementation of an institutional systems approach for newborn jaundice management is shown in Figure 1 . 18 Similarly, the use of phototherapy and exchange transfusion at a singlepayor, regional health maintenance organization study is shown in Table 4 . 19, 20 These data from the United States compare to the Jerusalem experience with 1 in 4520 infants requiring an exchange transfusion, 1.9% requiring hospital-based intensive phototherapy and 0.41% being readmitted for phototherapy. 21 Question 6: What is the estimated risk of kernicterus in infants with excessive hyperbilirubinemia? There has been an historic concern that untreated TSB X30 mg per 100 ml was more likely to be associated with irreversible kernicterus. We estimate the risk of kernicterus in infants with extreme hyperbilirubinemia using contemporary population-based data from Canada and Denmark. In Canada, the incidence of TSB >25 mg per 100 ml is 1 in 2840 and the concurrent incidence of chronic kernicterus is 1 in 50 000. Thus, risk of kernicterus in infants with TSB >25 mg per 100 ml may be calculated as 50 000/ 2840 or 1 in 17.6. In Denmark, the incidence of TSB >25 mg per 100 ml was 1 in 4320 for a concurrent incidence of kernicterus as 1 in 70 000. Thus, risk of kernicterus in infants with TSB >25 mg per 100 ml in Denmark was estimated as 1 in 16.2 (70 000/4320). The British and Danish studies define incidences of TSB X30 mg per 100 ml as 1 in 14 084 and 1 in 10 000 live births and kernicterus incidence of 1 and 1.4/100 00 live births, respectively. Thus, the risk of kernicterus in infants with TSB >30 mg per 100 ml is about one in seven. [15] [16] [17] The risk is 1 in 5.5, assuming 2 of the 11 infants with TSB >30 mg per 100 ml 'lost to follow-up' in the California data have kernicterus. 24 None of these retrospective data provide any insight to signs of acute kernicterus in infants with TSB <25 mg per 100 ml.
Question 7: Is there a specific threshold TSB value for bilirubin related neurotoxicity? As discussed in a recent review, previous investigators have unsuccessfully attempted to correlate the occurrence of kernicterus to a specific or threshold TSB level. 25 In this supplement, the report from the Pilot USA Kernicterus Registry also fails to identify a specific TSB level that is associated with the onset of bilirubin neurotoxicity. It appears that bilirubin levels of >35 mg per 100 ml (598 mmol l À1 ) can have profoundly deleterious effect. Data are needed to document clinical signs of acute kernicterus to a range of TSB levels and unbound bilirubin levels. 13 1 in 50 000 United States: health system 23 6 1 in 27 000 United States: regional health 19 2 a 1 in 55 000
The incidence of acute kernicterus (ABE) in the United States is estimated at 1 in 40 000 live births based on these data and the ability to prevent post-icteric sequelae with crashcart approach. These data need to be verified by prospective surveillance. a Two cases reported as 'lost to follow-up' and assumed to have kernicterus. 26, 27 In their article, Soorani-Lunsing et al. 28 prospectively observed a dose-response relationship increase in minor neurological dysfunction throughout the first year of life to the degree of hyperbilirubinemia (13.6 to 25 mg per 100 ml; 233 to 444 mmol l À1 ). Are moderate degrees of hyperbilirubinemia really safe for the brain? This question remains unanswered. Minor neurological abnormalities have been described as abnormal postural behavior, highfrequency tremors and deviancies in muscle tone regulation at ages 3 and 12 months. These may continue beyond puberty as muscle tone dysregulation, choreiform dyskinesia, manipulative disability, coordination problems, gait abnormalities, awkwardness, tremors or exaggerated extrapyramidal reflexes. Their correlation to moderate or severe hyperbilirubinemia without concurrent signs of acute bilirubin encephalopathy has been sought but not proven. Prospective long-term clinical studies are needed to allay these concerns.
Question 9: Can we define a bilirubin level that is safe? Evidence needs to be determined. To assure a safe approach to manage newborn hyperbilirubinemia in a changing health-care environment, optimal operational thresholds for intervention need to be delineated. Consensus and evidence-based guidelines have been established and need to be implemented. 4 Clinical experience and practices indicate that kernicterus can almost always be prevented in infants >35 weeks of gestation. Our experience with universal pre-discharge bilirubin screening in the well-baby nursery indicates that hour-specific TSB levels <40th percentile appear to be safe in terms of the magnitude of hyperbilirubinemia and the potential risk for subsequent adverse outcome during the first week after birth. Figure 1 Rates of readmission for well babies pre-, during and subsequent to implementation of systems-based approach for newborn jaundice (from Bhutani et al.
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). Question 10: Can we prevent kernicterus by a practical approach?
In infants >35 weeks GA, kernicterus should be unacceptable. Prevention of kernicterus should be a public health goal. As the 2004 guidelines 12 is implemented, success for reduction in the incidence of severe hyperbilirubinemia and possibly kernicterus has yet to be shown through national surveillance.
The ensuing articles and a report from the Pilot USA Kernicterus Registry, presented in this supplement, provide a current perspective on these questions and inform strategies to transform management of newborn jaundice.
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